Research Triangle Park, NC, November 19, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fennec’s outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP using proceeds from the closing of the […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES COMPLETION OF FULL DEBT REDEMPTION
Research Triangle Park, NC, November 17, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its non-brokered offering of its common shares in Canada, at a price of US$7.50 per share, with certain of its existing institutional shareholders, for aggregate gross proceeds of US$5,025,000. […]
Research Triangle Park, NC, November 17, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares (which amount includes exercise in full of the underwriters’ option to purchase additional common shares) at a public offering price […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES CLOSING OF OFFERING OF COMMON SHARES
Research Triangle Park, NC, November 13, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its underwritten registered public offering of 4,666,667 common shares at a public offering price of $7.50 per share. In addition, Fennec has granted the underwriters a 30-day option to […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES PRICING OF OFFERING OF COMMON SHARES
Research Triangle Park, NC, November 13, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-brokered offering of its common shares in Canada, at a price of US$7.50 per share, with certain of its existing institutional shareholders, for aggregate gross […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES PRIVATE OFFERING OF COMMON SHARES IN CANADA
~ Q3 2025 Total Net Product Sales of $12.5 Million, 79% Year Over Year Growth ~ ~ Q3 2025 Positive Cash Flow from Operations, Cash Position Grew to $22 Million ~ ~ Japan Clinical Trial (STS-J01) Preliminary Results Expected in Q4 2025 ~ Research Triangle Park, NC, November 13, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), […]
Research Triangle Park, NC, November 13, 2025 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to offer and sell its common shares in an underwritten registered public offering. In addition, Fennec intends to grant the underwriters a 30-day option to purchase up to an […]
Read More… from FENNEC PHARMACEUTICALS ANNOUNCES PROPOSED OFFERING OF COMMON SHARES
FENNEC PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Practices and Academic Centers, Supported by Targeted Sales Strategy and Enhanced Patient Support […]
Research Triangle Park, NC — (GlobeNewswire) –June 3, 2025 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 25, 2025 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on […]
~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company’s Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI® Now Commercially Available in Germany and the United Kingdom ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ Research Triangle […]